Matthew E. Ros
Net Worth
Last updated:
What is Matthew E. Ros net worth?
The estimated net worth of Mr. Matthew E. Ros is at least $6,268,907 as of 4 Feb 2021. He owns shares worth $121,454 as insider, has earned $1,709,103 from insider trading and has received compensation worth at least $4,438,350 in Epizyme, Inc..
What is the salary of Matthew E. Ros?
Mr. Matthew E. Ros salary is $634,050 per year as Advisor in Epizyme, Inc..
How old is Matthew E. Ros?
Mr. Matthew E. Ros is 58 years old, born in 1967.
What stocks does Matthew E. Ros currently own?
As insider, Mr. Matthew E. Ros owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Epizyme, Inc. (EPZM) | Advisor | 83,188 | $1.46 | $121,454 |
What does Epizyme, Inc. do?
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..
Matthew E. Ros insider trading
Epizyme, Inc.
Mr. Matthew E. Ros has made 9 insider trades between 2018-2021, according to the Form 4 filled with the SEC. Most recently he sold 894 units of EPZM stock worth $10,022 on 4 Feb 2021.
The largest trade he's ever made was exercising 112,003 units of EPZM stock on 18 Jun 2020. As of 4 Feb 2021 he still owns at least 83,188 units of EPZM stock.
Epizyme key executives
Epizyme, Inc. executives and other stock owners filed with the SEC:
- Dr. Jeffery L. Kutok (58) Chief Scientific Officer
- Dr. Shefali Agarwal M.D., MPH (51) Executive Vice President and Chief Medical & Devel. Officer
- Mr. Grant C. Bogle (67) Pres, Chief Executive Officer, Principal Financial Officer & Director
- Mr. Matthew E. Ros (58) Advisor